Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > It seems like..
View:
Post by scarlet1967 on Jan 10, 2023 2:57pm

It seems like..

 

That it’s not only THTX who believes two long acting drugs regime is the path forward…

 

“However, despite findings of efficacy in studies when given daily, weekly, or as an injection up to every 6 months, lenacapavir is dependent on antiretroviral drugs that must be given daily.

 

These are undoubtedly promising results; however, lenacapavir needs a long-acting partner if it is to deliver on its promise of being part of a comprehensive long-acting regimen,” noted Chloe Orkin, MBBCH, of the University Queen Mary in London, writing in a commentary accompanying the study. "With the development of islatravir slowed by unexpected immunological findings, the identity of this partner is far from clear."

 

https://lesactualites.news/sante/medicament-anti-vih-a-action-prolongee-prometteur-pour-les-patients-naifs-de-traitement/

Comment by scarlet1967 on Jan 10, 2023 3:21pm
"Regimen"
Comment by Wino115 on Jan 10, 2023 4:03pm
Now that would be a nice sales partner. Get that combo drug plan going THTX.
Comment by scarlet1967 on Jan 10, 2023 4:25pm
We could say the same for their NASH asset, despite the promising results from mono therapies recently a combo therapy would be needed to tackle a condition like NASH heterogeneous, growing prevalence and estimated market at $35 billion....
Comment by Trogarzon on Jan 10, 2023 4:33pm
The market panicked beyond stupid in december.  The analysts did'nt budge on the pause news.  We're oversold by a mile.  The only crooks here are the negative posts and the ambulance chasers that work hand in hand with the shorts.  
Comment by Momo25 on Jan 10, 2023 8:44pm
Mind your business. The crooks are the ones who help this board keeping the investors in the dark. We are fighting for our money. Maybe you have 1000 shares or even less and you feel like an investor. As far as I am concerned, now the harm was done to my portfolio, I have to give it a try, a last one, a kind of gamble: buying enough shares when the share hits $0,8 so I can average to $3 and ignore ...more  
Comment by Trogarzon on Jan 10, 2023 8:47pm
I don't think you call me stupid if I was in front of you.
Comment by Momo25 on Jan 11, 2023 5:00am
I am sure I can.
Comment by houbahop on Jan 11, 2023 5:25am
"...The only crooks here are the negative posts and the ambulance chasers that work hand in hand with the shorts." Are you dellusional? There is virtually no short position on this stock. There is no volume and almost no downside. The negative posts on this forum are a lot closer to reality of this company than all the positive posts. Now the proof is lying in the hands of Thera BoD ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities